Moreover, research conducted by Kim et al. (2022) and Almeida et al. (2020) indicated that focusing on the lysosomal pathway, specifically cathepsin B, could potentially become a highly effective therapeutic approach not only for PD but also for various other neurodegenerative disorders. This evidence concerns the gene CTSB and Parkinson disease.